Novartis at Q2

Country

Switzerland

Novartis saw its operating profit decline in the second quarter but sales of core products such as Entresto for heart failure and Kisqali for breast cancer delivered double-digit sales growth. Turnover for the group as a whole was $12.8 billion, down by 1% from a year earlier. Measured at constant exchange rates, group sales increased by 5%.